Natural Field Releases Research Findings on NFTriSolve® Co-Loading Liposome Formula
XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research results show that the NFTriSolve® four-component formula demonstrates significant advantages over traditional formulations,...
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy....
The Benefits of Prostate Cancer Screening Outweigh the Harms, According to New Patient Guidelines From NCCN
Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive testing in order to avoid unnecessary procedures and treatment while at the same time saving lives. PLYMOUTH MEETING, Pa., April 28, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—has published a new book explaining the latest evidence and expert recommendations around prostate...
ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery
SAN DIEGO and NEWARK, N.J., April 28, 2026 /PRNewswire/ -- From April 17 to 22, 2026, ACROBiosystems—a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries—presented its comprehensive, AI‑driven protein solutions at the American Association for Cancer Research (AACR) Annual Meeting 2026. Dr. Yu Sun, VP of Product Development, delivered a presentation titled "Leveraging AI...
C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER CHLORIDE FOR RADIOLABELLING has been listed as active by the U.S. Food and Drug Administration (FDA) under DMF...
Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer
SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer. Dr. Shah will lead the Company's global clinical development and medical affairs at an inflection point...
World’s First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical
CHONGQING, China, April 28, 2026 /PRNewswire/ -- Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of moderate-to-severe glabellar lines in adult patients. Retoxin® is the world's first approved recombinant botulinum toxin type A, marking a significant...
Echosens Appoints Romain Baujard as Group Chief Executive Officer
Company to accelerate its mission to make liver health a vital sign in cardiometabolic care; appointment follows retirement of current Group CEO Dominique Legros PARIS, April 28, 2026 /PRNewswire/ -- Echosens, a global diagnostic company specializing in non-invasive medical devices and services, today announced the appointment of Romain Baujard as Group Chief...
Ping An Reports Steady 7.6% Growth in Operating Profit Attributable to Shareholders of the Parent Company in Q1 2026, Life & Health NBV Increases 20.8% YoY
Group Total Assets Exceed RMB14 Trillion HONG KONG and SHANGHAI, April 28, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group"; HKEX: 2318; SSE: 601318) today announced its first quarter financial results for the three months ended March 31, 2026. 2026 marks the commencement of China's 15th Five-Year Plan. Despite...
Waterdrop Files Annual Report on Form 20-F for Fiscal Year 2025
BEIJING, April 28, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on April...
